Physician profile
Beny Rub
NPI 1306802186
$945.42
in general payments reported to CMS, 2019-2025
14 companies · $152 in 2025
The $152 reported for 2025 was more than what a typical Pediatrics provider received nationally (typical 2025 total: $96.93).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $229 · 2020: $138 · 2021: $118 · 2022: $22.03 · 2023: $105 · 2024: $181 · 2025: $152.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $438.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $438.29 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Welch Allyn | $320.45 | 2019-2020 | |
| Cranial Technologies, INC | $118.67 | 2021-2025 | Doc Band |
| Astrazeneca Pharmaceuticals LP | $82.78 | 2024 | |
| Glaxosmithkline, LLC. | $74.33 | 2021-2025 | Bexsero, Rotarix, Pediarix |
| Sanofi Pasteur INC. | $67.26 | 2023-2025 | |
| Ironshore Pharmaceuticals INC. | $49.45 | 2020-2022 | |
| Sanofi-Aventis U.S. LLC | $47.37 | 2025 | |
| Cmp Pharma, INC. | $40.57 | 2023 | Atorvaliq, Carospir, Norliqva |
| Pfizer INC. | $35.78 | 2019-2024 | |
| Merck Sharp & Dohme LLC | $27.20 | 2023 | M-M-R II, Gardasil 9, Vaxelis |
| Alk-Abello, INC | $22.99 | 2025 | Neffy |
| Ultragenyx Pharmaceutical INC. | $21.11 | 2021 | |
| Mission Pharmacal Company | $19.29 | 2019 | |
| Phadia US INC. | $18.17 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Beny Rub listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.